Beijing Joant Bio-Tech Co., Ltd. · 99-39 · CHINA
For Beijing Joant Bio-Tech Co., Ltd. · 99-39 · CHINA, import alert is 99-39; import alert name is Detention Without Physical Examination of Imported Food Products That Appear to Be Misbranded; country is CHINA; product is Biotin | Gingkgo Biloba | Saw Palmetto | Gingkgo Biloba | Saw Palmetto; product code is 54 A - - 17 Biotin (Vitamin H, Coenzyme R) | 54 E - - 48 Ginkgo biloba (Herbal & Botanical Teas) | 54 E - - 58 Saw Palmetto (Herbal & Botanical Teas) | 54 F - - 48 Ginkgo biloba (Herbal & Botanicals, not Teas) | 54 F - - 58 Saw Palmetto (Herbal & Botanicals, not Teas) | 54 - - - -- Vitamins/Minerals (Human/Animal); Proteins/Unconv Dietary Supp (Human); date published is 04/06/2015; address is 25 Yanqi Street; Economic Development Zone , Huairou, Beijing CHINA, verified against its source on 2026-09-16.
- Firm
- Beijing Joant Bio-Tech Co., Ltd. verified
- Import alert
- 99-39
- Import alert name
- Detention Without Physical Examination of Imported Food Products That Appear to Be Misbranded
- Country
- CHINA verified
- Address
- 25 Yanqi Street; Economic Development Zone , Huairou, Beijing CHINA verified
- Date published
- 04/06/2015 verified
- Product code
- 54 A - - 17 Biotin (Vitamin H, Coenzyme R) | 54 E - - 48 Ginkgo biloba (Herbal & Botanical Teas) | 54 E - - 58 Saw Palmetto (Herbal & Botanical Teas) | 54 F - - 48 Ginkgo biloba (Herbal & Botanicals, not Teas) | 54 F - - 58 Saw Palmetto (Herbal & Botanicals, not Teas) | 54 - - - -- Vitamins/Minerals (Human/Animal); Proteins/Unconv Dietary Supp (Human) each item verified
- Product
- Biotin | Gingkgo Biloba | Saw Palmetto | Gingkgo Biloba | Saw Palmetto each item verified
- FDA notes
- Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement | Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement. In addition, Section 403(e)(1) in that it fails to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(d). | Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement. In addition, Section 403(e)(1) in that it fails to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(d). | Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement. In addition, Section 403(e)(1) in that it fails to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(d). | Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement. In addition, Section 403(e)(1) in that it fails to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(d). | Lycopene;Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement. In addition, Section 403(e)(1) in that it fails to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(d). each item verified
What the source says
Beijing Joant Bio-Tech Co., Ltd. Date Published : 04/06/2015 25 Yanqi Street; Economic Development Zone , Huairou, Beijing CHINA 54 A - - 17 Biotin (Vitamin H, Coenzyme R) Date Published: 04/06/2015 Desc: Biotin Notes: Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement 54 E - - 48 Ginkgo biloba (Herbal & Botanical Teas) Date Published: 04/06/2015 Desc: Gingkgo Biloba Notes: Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement. In addition, Section 403(e)(1) in that it fails to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(d). 54 E - - 58 Saw Palmetto (Herbal & Botanical Teas) Date Published: 04/06/2015 Desc: Saw Palmetto Notes: Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement. In addition, Section 403(e)(1) in that it fails to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(d). 54 F - - 48 Ginkgo biloba (Herbal & Botanicals, not Teas) Date Published: 04/06/2015 Desc: Gingkgo Biloba Notes: Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement. In addition, Section 403(e)(1) in that it fails to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(d). 54 F - - 58 Saw Palmetto (Herbal & Botanicals, not Teas) Date Published: 04/06/2015 Desc: Saw Palmetto Notes: Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement. In addition, Section 403(e)(1) in that it fails to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(d). 54 - - - -- Vitamins/Minerals (Human/Animal); Proteins/Unconv Dietary Supp (Human) Date Published: 04/06/2015 Notes: Lycopene;Notes(s): The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded within the meaning of Section 403(a)(1) in that the labels are false or misleading because the amount of nutrient present is less than the amount declared on the label. Specifically, FDA analyzed samples of the Calcium soft capsule to determine whether the label accurately reflects the nutrition content of the products. The Calcium soft capsule Production Plan Form states that the product provides 1000 mg/capsule. However, FDA analysis found the calcium content in the firm's Calcium soft capsule product to be 22.9% (original analysis) and 23.9% (check analysis) of the amount set in the Production Plan Form. In addition, Section 403(i)(2) as the product is fabricated from two or more ingredients, and the label fails to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. Specifically, the product label does not have an ingredient statement. In addition, Section 403(e)(1) in that it fails to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(d).
— accessdata.fda.gov, retrieved 2026-09-15
Source
- accessdata.fda.govhttps://www.accessdata.fda.gov/cms_ia/importalert_1144.html
This one changes, and we watch it.FDA import alert red lists: firms subject to detention without physical examination is re-read on a schedule and every change is dated. Subscribe: Atom feed · JSON · what has changed so far.